

Robert B Zipursky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3188072/publications.pdf>

Version: 2024-02-01

121
papers

9,377
citations

31902

53
h-index

38300

95
g-index

123
all docs

123
docs citations

123
times ranked

7383
citing authors

#	ARTICLE	IF	CITATIONS
1	Do anxiety and depression symptoms moderate the effect of motivational enhancement therapy as a pretreatment to dialectical behaviour therapy skills training? A follow-up analysis of a pilot randomised controlled trial for youth. <i>Microbial Biotechnology</i> , 2021, , .	0.9	0
2	Alvin Zipursky (1930–2021): an unsurpassable mentor, counselor, and child health advocate. <i>Pediatric Research</i> , 2021, , .	1.1	0
3	Rethinking service design for youth with mental health needs: The development of the Youth Wellness Centre, St. Joseph's Healthcare Hamilton. <i>Microbial Biotechnology</i> , 2020, 14, 365-372.	0.9	7
4	Modeling the Reduction of Attrition in Campus Mental Health Services: A Discrete Choice Conjoint Experiment. <i>Emerging Adulthood</i> , 2020, , 216769682094689.	1.4	1
5	You say "schizophrenia" and I say "psychosis" Just tell me when I can come off this medication. <i>Schizophrenia Research</i> , 2020, 225, 39-46.	1.1	11
6	Motivational Enhancement as a Pretreatment to a Transdiagnostic Intervention for Emerging Adults with Emotion Dysregulation: A Pilot Randomized Controlled Trial. <i>Journal of the Canadian Academy of Child and Adolescent Psychiatry</i> , 2020, 29, 132-148.	0.7	1
7	Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1036-1042.	2.8	116
8	Investigating service features to sustain engagement in early intervention mental health services. <i>Microbial Biotechnology</i> , 2019, 13, 241-250.	0.9	5
9	Understanding and Managing Treatment Adherence in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2019, , .	1.4	13
10	Improving outcomes in schizophrenia by preventing early relapses. <i>Lancet Psychiatry</i> , the, 2018, 5, 384-386.	3.7	8
11	Rapid remission of first-episode schizophrenia with standardised treatment. <i>Lancet Psychiatry</i> , the, 2018, 5, 770-771.	3.7	2
12	Characterizing outcome preferences in patients with psychotic disorders: a discrete choice conjoint experiment. <i>Schizophrenia Research</i> , 2017, 185, 107-113.	1.1	12
13	Modeling the mental health service utilization decisions of university undergraduates: A discrete choice conjoint experiment. <i>Journal of American College Health</i> , 2017, 65, 389-399.	0.8	22
14	Imagining schizophrenia without relapses. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 764-765.	1.3	1
15	Preferences for Early Intervention Mental Health Services: A Discrete-Choice Conjoint Experiment. <i>Psychiatric Services</i> , 2016, 67, 184-191.	1.1	18
16	Values in First-Episode Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 507-514.	0.9	8
17	Recovery, not progressive deterioration, should be the expectation in schizophrenia. <i>World Psychiatry</i> , 2015, 14, 94-96.	4.8	33
18	Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review. <i>Schizophrenia Research</i> , 2014, 152, 408-414.	1.1	172

#	ARTICLE	IF	CITATIONS
19	Event-related brain potential study of semantic priming in unaffected first-degree relatives of schizophrenia patients. <i>Schizophrenia Research</i> , 2014, 153, 78-86.	1.1	16
20	Why Are the Outcomes in Patients With Schizophrenia So Poor?. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 20-24.	1.1	42
21	Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study. <i>Psychopharmacology</i> , 2013, 225, 95-104.	1.5	9
22	Test-retest reliability and stability of N400 effects in a word-pair semantic priming paradigm. <i>Clinical Neurophysiology</i> , 2013, 124, 667-674.	0.7	26
23	Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970-2010. <i>American Journal of Psychiatry</i> , 2013, 170, 1335-1344.	4.0	112
24	The Myth of Schizophrenia as a Progressive Brain Disease. <i>Schizophrenia Bulletin</i> , 2013, 39, 1363-1372.	2.3	274
25	A "navigator" model in emerging mental illness?. <i>Microbial Biotechnology</i> , 2013, 7, 451-457.	0.9	22
26	Electrophysiological evidence for primary semantic memory functional organization deficits in schizophrenia. <i>Psychiatry Research</i> , 2012, 196, 171-180.	1.7	24
27	MRI-targeted repetitive transcranial magnetic stimulation of Heschl's gyrus for refractory auditory hallucinations. <i>Brain Stimulation</i> , 2012, 5, 577-585.	0.7	48
28	Happiness in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2012, 141, 98-103.	1.1	45
29	Treating young individuals at clinical high risk for psychosis. <i>Microbial Biotechnology</i> , 2012, 6, 60-68.	0.9	27
30	A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. <i>Schizophrenia Research</i> , 2011, 125, 54-61.	1.1	209
31	Depth-of-processing effects on semantic activation deficits in schizophrenia: An electrophysiological investigation. <i>Schizophrenia Research</i> , 2011, 133, 91-98.	1.1	14
32	Reshaping an enduring sense of self: the process of recovery from a first episode of schizophrenia. <i>Microbial Biotechnology</i> , 2010, 4, 243-250.	0.9	41
33	Examining the Effects of Enhanced Funding for Specialized Community Mental Health Programs on Continuity of Care. <i>Canadian Journal of Community Mental Health</i> , 2010, 29, 23-40.	0.1	14
34	Second generation antipsychotics are not superior in relieving family burden in schizophrenia compared with the first generation antipsychotic perphenazine. <i>Evidence-Based Mental Health</i> , 2010, 13, 84-84.	2.2	0
35	The Dopamine D2 Receptors in High-Affinity State and D3 Receptors in Schizophrenia: A Clinical [11C]-(+)-PHNO PET Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1078-1086.	2.8	109
36	Specialized home treatment versus hospital-based outpatient treatment for first-episode psychosis: a randomized clinical trial. <i>Microbial Biotechnology</i> , 2009, 3, 304-311.	0.9	3

#	ARTICLE	IF	CITATIONS
37	Early detection of psychosis: finding those at clinical high risk. <i>Microbial Biotechnology</i> , 2008, 2, 147-153.	0.9	33
38	Cerebral white matter deficiencies in pedophilic men. <i>Journal of Psychiatric Research</i> , 2008, 42, 167-183.	1.5	159
39	Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. <i>Schizophrenia Research</i> , 2008, 105, 1-9.	1.1	79
40	The Formation of Abnormal Associations in Schizophrenia: Neural and Behavioral Evidence. <i>Neuropsychopharmacology</i> , 2008, 33, 473-479.	2.8	195
41	Cognitive Function and Brain Structure in Females With a History of Adolescent-Onset Anorexia Nervosa. <i>Pediatrics</i> , 2008, 122, e426-e437.	1.0	117
42	Illness Intrusiveness and Subjective Well-Being in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 798-805.	0.5	9
43	Adverse Subjective Experience With Antipsychotics and Its Relationship to Striatal and Extrastriatal D ₂ Receptors: a PET Study in Schizophrenia. <i>American Journal of Psychiatry</i> , 2007, 164, 630-637.	4.0	141
44	Striatal Vs Extrastriatal Dopamine D2 Receptors in Antipsychotic Response—A Double-Blind PET Study in Schizophrenia. <i>Neuropsychopharmacology</i> , 2007, 32, 1209-1215.	2.8	118
45	The effect of antipsychotic treatment on Theory of Mind. <i>Psychological Medicine</i> , 2007, 37, 595.	2.7	64
46	PET and SPECT Imaging in Psychiatric Disorders. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 146-157.	0.9	79
47	Imaging Mental Disorders in the 21st Century. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 133-134.	0.9	3
48	A randomised controlled trial of a group intervention to reduce engulfment and self-stigmatisation in first episode schizophrenia. <i>Australian E-Journal for the Advancement of Mental Health</i> , 2007, 6, 212-220.	0.2	28
49	Early Use of Clozapine for Poorly Responding First-Episode Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 369-373.	0.7	82
50	4: Effects of menstrual function and weight restoration on cognitive function in females with adolescent-onset anorexia nervosa. <i>Journal of Adolescent Health</i> , 2007, 40, S12.	1.2	5
51	Inconsistency in the relationship between duration of untreated psychosis (DUP) and negative symptoms: Sorting out the problem of heterogeneity. <i>Schizophrenia Research</i> , 2007, 93, 152-159.	1.1	24
52	Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. <i>Schizophrenia Research</i> , 2006, 83, 53-63.	1.1	135
53	A longitudinal study of neurocognitive function in individuals at-risk for psychosis. <i>Schizophrenia Research</i> , 2006, 88, 26-35.	1.1	236
54	The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2006, 88, 111-118.	1.1	52

#	ARTICLE	IF	CITATIONS
55	Substance Use and Abuse in First-Episode Psychosis: Prevalence Before and After Early Intervention. <i>Schizophrenia Bulletin</i> , 2006, 33, 1354-1363.	2.3	89
56	Gender, age, ethnicity and area of residence influence incidence of psychotic disorders. <i>Evidence-Based Mental Health</i> , 2006, 9, 107-107.	2.2	1
57	Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. <i>American Journal of Psychiatry</i> , 2006, 163, 790-799.	4.0	500
58	Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. <i>British Journal of Psychiatry</i> , 2005, 187, 537-543.	1.7	183
59	Treatment Response to Olanzapine and Haloperidol and its Association with Dopamine D ₂ Receptor Occupancy in First-Episode Psychosis. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 462-469.	0.9	24
60	Volumetric MRI measurement of caudate nuclei in antipsychotic-naïve patients suffering from a first episode of psychosis. <i>Journal of Psychiatric Research</i> , 2005, 39, 365-370.	1.5	32
61	Specialised care for early psychosis may reduce number of readmissions. <i>Evidence-Based Mental Health</i> , 2005, 8, 34-34.	2.2	1
62	Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment. <i>American Journal of Psychiatry</i> , 2005, 162, 939-946.	4.0	193
63	How antipsychotics work: The patients' perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2005, 29, 859-864.	2.5	30
64	Pregnancy Outcome of Women Using Atypical Antipsychotic Drugs. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 444-449.	1.1	267
65	Equivalent Occupancy of Dopamine D ₁ and D ₂ Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics. <i>American Journal of Psychiatry</i> , 2004, 161, 1620-1625.	4.0	146
66	Stable deficits in gray matter volumes following a first episode of schizophrenia. <i>Schizophrenia Research</i> , 2004, 71, 515-516.	1.1	14
67	Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. <i>British Journal of Psychiatry</i> , 2004, 185, 18-24.	1.7	143
68	Effect of antipsychotics on cortical inhibition using transcranial magnetic stimulation. <i>Psychopharmacology</i> , 2003, 170, 255-262.	1.5	43
69	Effects of catecholamine depletion on D ₂ receptor binding, mood, and attentiveness in humans: a replication study. <i>Pharmacology Biochemistry and Behavior</i> , 2003, 74, 425-432.	1.3	76
70	Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. <i>Biological Psychiatry</i> , 2003, 54, 453-464.	0.7	194
71	Comparative Efficacy and Safety of Atypical and Conventional Antipsychotic Drugs in First-Episode Psychosis: A Randomized, Double-Blind Trial of Olanzapine Versus Haloperidol. <i>American Journal of Psychiatry</i> , 2003, 160, 1396-1404.	4.0	380
72	Increasing D ₂ affinity results in the loss of clozapine's atypical antipsychotic action. <i>NeuroReport</i> , 2002, 13, 831-835.	0.6	29

#	ARTICLE	IF	CITATIONS
73	Use of Atypical Antipsychotics During Pregnancy and the Risk of Neural Tube Defects in Infants. American Journal of Psychiatry, 2002, 159, 136-137.	4.0	65
74	Structural brain abnormalities in patients with schizophrenia and 22q11 deletion syndrome. Biological Psychiatry, 2002, 51, 208-215.	0.7	103
75	Visual feature conjunction in patients with schizophrenia: an event-related brain potential study. Schizophrenia Research, 2002, 57, 69-79.	1.1	17
76	Caudate volume changes in first episode psychosis parallel the effects of normal aging: a 5-year follow-up study. Schizophrenia Research, 2002, 58, 185-188.	1.1	31
77	The role of maintenance pharmacotherapy in achieving recovery from a first episode of schizophrenia. International Review of Psychiatry, 2002, 14, 284-292.	1.4	10
78	Deficits in automatically detecting changes in conjunction of auditory features in patients with schizophrenia. Psychophysiology, 2002, 39, 599-606.	1.2	31
79	Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade. Journal of Clinical Psychiatry, 2002, 63, 992-997.	1.1	71
80	Psychotic Recurrence After Antipsychotic Discontinuation. American Journal of Psychiatry, 2002, 159, 1441-a-1442.	4.0	0
81	Auditory feature conjunction in patients with schizophrenia. Schizophrenia Research, 2001, 49, 179-191.	1.1	19
82	Increased Dopamine D2Receptor Occupancy and Elevated Prolactin Level Associated With Addition of Haloperidol to Clozapine. American Journal of Psychiatry, 2001, 158, 311-314.	4.0	99
83	Starving the brain: Structural abnormalities and cognitive impairment in adolescents with anorexia nervosa. Seminars in Clinical Neuropsychiatry, 2001, 6, 146-152.	1.9	80
84	Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology, 2000, 152, 174-180.	1.5	249
85	A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT2A receptor changes in schizophrenia. Psychiatry Research - Neuroimaging, 2000, 99, 123-135.	0.9	49
86	Ethical issues in schizophrenia research. Current Psychiatry Reports, 1999, 1, 13-19.	2.1	1
87	Is amoxapine an atypical antipsychotic? positron-emission tomography investigation of its dopamine2 and serotonin2 occupancy. Biological Psychiatry, 1999, 45, 1217-1220.	0.7	70
88	Qualitative MRI findings in adults with 22q11 deletion syndrome and schizophrenia. Biological Psychiatry, 1999, 46, 1436-1442.	0.7	115
89	Serotonin 5-HT ₂ Receptors in Schizophrenia: A PET Study Using [¹⁸ F]Setoperone in Neuroleptic-Naive Patients and Normal Subjects. American Journal of Psychiatry, 1999, 156, 72-78.	4.0	108
90	An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Research, 1998, 81, 333-339.	1.7	32

#	ARTICLE	IF	CITATIONS
91	Temporal horn enlargement is present in schizophrenia and bipolar disorder. <i>Biological Psychiatry</i> , 1998, 44, 418-422.	0.7	79
92	MRI correlates of treatment response in first episode psychosis. <i>Schizophrenia Research</i> , 1998, 30, 81-90.	1.1	35
93	5-HT ₂ and D ₂ Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation. <i>American Journal of Psychiatry</i> , 1998, 155, 921-928.	4.0	359
94	Functional network differences in schizophrenia. <i>NeuroReport</i> , 1998, 9, 1697-1700.	0.6	55
95	Pharmacotherapy of first-episode schizophrenia. <i>British Journal of Psychiatry</i> , 1998, 172, 66-70.	1.7	68
96	New insights into schizophrenia from neuroimaging. <i>Current Opinion in Psychiatry</i> , 1998, 11, 33-37.	3.1	7
97	The Relationship Between Risperidone Plasma Levels and Dopamine D ₂ Occupancy. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 82-83.	0.7	23
98	APA Practice Guideline for Schizophrenia: Risperidone Equivalents. <i>American Journal of Psychiatry</i> , 1998, 155, 1301a-1302.	4.0	4
99	PET Evidence That Loxapine Is an Equipotent Blocker of 5-HT ₂ and D ₂ Receptors: Implications for the Therapeutics of Schizophrenia. <i>American Journal of Psychiatry</i> , 1997, 154, 1525-1529.	4.0	92
100	Relationship between negative symptoms in chronic schizophrenia and neuroleptic dose, plasma levels and side effects. <i>Schizophrenia Research</i> , 1997, 25, 71-78.	1.1	18
101	Deficits in gray matter volume are present in schizophrenia but not bipolar disorder ¹ This work was presented at the Meeting of the Society of Biological Psychiatry, Philadelphia, PA, USA, May 1994.1. <i>Schizophrenia Research</i> , 1997, 26, 85-92.	1.1	101
102	Volumetric MRI study of first episode schizophrenia. <i>Schizophrenia Research</i> , 1997, 24, 161.	1.1	1
103	Adolescents with Anorexia Nervosa: The Impact of the Disorder on Bones and Brains. <i>Annals of the New York Academy of Sciences</i> , 1997, 817, 127-137.	1.8	30
104	The relationship between D ₂ receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. <i>Psychopharmacology</i> , 1997, 131, 148-152.	1.5	118
105	Cortical gray matter volume deficits in schizophrenia: a replication. <i>Schizophrenia Research</i> , 1996, 20, 157-164.	1.1	57
106	Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia. <i>Biological Psychiatry</i> , 1996, 39, 234-240.	0.7	56
107	Cerebral gray matter and white matter volume deficits in adolescent girls with anorexia nervosa. <i>Journal of Pediatrics</i> , 1996, 129, 794-803.	0.9	154
108	The D ₂ dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet study. <i>Life Sciences</i> , 1995, 57, PL103-PL107.	2.0	204

#	ARTICLE	IF	CITATIONS
109	Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. <i>Psychopharmacology</i> , 1994, 116, 291-296.	1.5	10
110	Volumetric MRI assessment of temporal lobe structures in schizophrenia. <i>Biological Psychiatry</i> , 1994, 35, 501-516.	0.7	203
111	A deficit profile of executive, memory, and motor functions in schizophrenia. <i>Biological Psychiatry</i> , 1994, 36, 641-653.	0.7	94
112	Factors of the Wisconsin Card Sorting Test as measures of frontal-lobe function in schizophrenia and in chronic alcoholism. <i>Psychiatry Research</i> , 1993, 46, 175-199.	1.7	183
113	Brain Gray and White Matter Volume Loss Accelerates with Aging in Chronic Alcoholics: A Quantitative MRI Study. <i>Alcoholism: Clinical and Experimental Research</i> , 1992, 16, 1078-1089.	1.4	525
114	The contribution of constructional accuracy and organizational strategy to nonverbal recall in Schizophrenia and chronic alcoholism. <i>Biological Psychiatry</i> , 1992, 32, 312-333.	0.7	51
115	Neuroimaging studies of schizophrenia. <i>Schizophrenia Research</i> , 1991, 4, 193-208.	1.1	45
116	Brain Size in Schizophrenia. <i>Archives of General Psychiatry</i> , 1991, 48, 179.	13.8	20
117	Volumetric assessment of cerebral asymmetry from CT scans. <i>Psychiatry Research - Neuroimaging</i> , 1990, 35, 71-89.	0.9	49
118	A quantitative analysis of CT and cognitive measures in normal aging and Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 1990, 35, 115-136.	0.9	43
119	In vivo quantification of the limbic system using MRI: Effects of normal aging. <i>Psychiatry Research - Neuroimaging</i> , 1990, 35, 15-26.	0.9	60
120	Clinical and neuropsychologic characteristics of schizophrenics showing impairment on the luria-nebraska neuropsychological battery. <i>Schizophrenia Research</i> , 1989, 2, 61.	1.1	3
121	MRI Study of Brain Changes with Short-Term Abstinence from Alcohol. <i>Alcoholism: Clinical and Experimental Research</i> , 1989, 13, 664-667.	1.4	84